| Today's Top Story |  |  | | - FDA expedites review of BioMarin's rare-disease drug Vimizim
The FDA has accepted BioMarin Pharmaceutical's biologics license application for Vimizim, or BMN-110, elosulfase alfa, an experimental treatment for Mucopolysaccharidosis type IVA, also known as Morquio A Syndrome. The enzyme replacement therapy was granted a priority-review status. RTT News (5/30)       - Abbott gains OK for HPV test in Canada
Abbott has received clearance in Canada to market its RealTime High Risk HPV system, which is used to spot 14 high-risk genotypes of human papillomavirus as well as the HPV genotypes 18 and 16 often linked to cervical cancer. The assay, which runs on the company's m2000 RealTime molecular diagnostic platform, earned the CE mark in 2008. GenomeWeb Daily News (free registration) (5/29) - More clinical trials using adaptive design
More clinical trials are being designed to end early if drugs prove ineffective, to add patients in order to achieve a statistically significant outcome or to incorporate other adaptive design elements, a Tufts Center for the Study of Drug Development report found. The most common barrier to adoption of adaptive design was internal organizational resistance rather than lack of regulatory agency support, the researchers found. Adaptive design could save trial sponsors up to $200 million annually, the study found. PharmaTimes (U.K.) (5/28)  | Webcast: A Conversation with The Johns Hopkins Hospital on Lowering the Cost of Healthcare from Inside Out
Learn how The Johns Hopkins Hospital uses its Integrated Asset and Service Management solution to improve uptime to support patient care; control costs for procurement, maintenance, labor and materials; support regulatory compliance activities; and use workflow capabilities for internal controls. Watch the webcast. |
 | Company & Financial News | | | | - Ophthotech lands $175M for late-stage trial of wet AMD drug
Ophthotech secured $175 million in new financing, and it will use the money to launch an international late-stage trial of Fovista, its lead anti-platelet-derived growth factor compound, in patients with wet age-related macular degeneration. The funding consists of $50 million from a Series C preferred stock offering and $125 million from Novo Nordisk in a royalty deal. Xconomy/New York (5/29), Healio/OSN Retina (5/29) | Food & Agriculture | | | | | Industrial & Environmental | | | |  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Industrial biotechnology with a French twist!
Over 1,300 leaders in biofuels, biobased products and renewable chemicals will be in Montreal June 16-19 for the 10th Annual BIO World Congress on Industrial Biotechnology. Join the impressive list of attendees for great food, excellent wine, and a can't miss program which will feature plenary sessions, breakout tracks, workshops, investor sessions, poster presentations, an exhibit hall, networking receptions, and business partnering. BIO is excited to bring this conference to Montreal, highlighting the industry's growth and the importance for generating green jobs and producing greener products and cleaner processes, all aimed at building a biobased economy. Learn more.
| SmartQuote | | | |  | A ship in port is safe, but that's not what ships are built for."
--Grace Murray Hopper,
U.S. Navy officer and computer scientist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Thursday, May 30, 2013
- Wednesday, May 29, 2013
- Tuesday, May 28, 2013
- Friday, May 24, 2013
- Thursday, May 23, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment